Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | FYN | P06241 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.41 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21826652 | 0.81 | AKR1C4 (0.44) | HSD17B10TSHRLCKFYNCA12 | |
| SCHEMBL21246826 | 0.81 | CA1 (0.42) | HSD17B10TSHRCA12CA1CA2 | |
| SCHEMBL8220004 | 0.81 | KDM4E (0.60) | HSD17B10TSHRLCKFYNCA12 | |
| SCHEMBL22807058 | 0.79 | GABRP (0.47) | HSD17B10TSHRLCKFYNKDM4E | |
| SCHEMBL1998749 | 0.79 | NAPRT (0.42) | HSD17B10TSHRLCKFYNCA12 | |
| SCHEMBL22717759 | 0.79 | KDM4E (0.44) | HSD17B10TSHRLCKFYNCA12 | |
| SCHEMBL4790109 | 0.79 | GABRP (0.56) | HSD17B10TSHRLCKFYNCA12 | |
| SCHEMBL19278516 | 0.79 | KDM4E (0.36) | HSD17B10TSHRLCKFYNCA12 | |
| SCHEMBL14901955 | 0.79 | HSD17B10 (0.44) | HSD17B10TSHRLCKFYNCA12 | |
| SCHEMBL5710659 | 0.79 | ALDH1A1 (0.44) | TSHRCA12CA1CA2CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2888247-B1 | SERINE/THREONINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | ARRAY BIOPHARMA INC (US) | 2020-03-25 | — | — | EP | disclosed |
| CN-105143200-B | Serine/threonine kinase inhibitor for treating excess proliferative disease | 阵列生物制药公司 | 2018-10-16 | — | — | CN | disclosed |
| WO-2018019758-A1 | HERBICIDAL PYRIDINE COMPOUNDS | BASF SE (DE) | 2018-02-01 | — | — | WO | disclosed |
| US-9388171-B2 | Serine/threonine kinase inhibitors | GENETECH, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| CN-105143200-A | Serine/threonine kinase inhibitors for the treatment of hyperproliferative|diseases | ARRAY BIOPHARMA INC | 2015-12-09 | — | — | CN | disclosed |
| CN-102272103-B | ISONICOTINAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-10-21 | — | — | CN | disclosed |
| EP-2888247-A1 | SERINE/THREONINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE!DISEASES | Array Biopharma, Inc. (US) | 2015-07-01 | — | — | EP | disclosed |
| EP-2350010-B1 | ISONICOTINAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-03-26 | — | — | EP | disclosed |
| EP-2350010-B1 | ISONICOTINAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-03-26 | — | — | EP | disclosed |
| WO-2014036015-A1 | SERINE/THREONINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE|DISEASES | ARRAY BIOPHARMA INC. (US) | 2014-03-06 | — | — | WO | disclosed |
| US-20140066453-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-8592457-B2 | Isonicotinamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-11-26 | — | — | US | disclosed |
| US-20110201591-A1 | ISONICOTINAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2011-08-18 | — | — | US | disclosed |
| US-20110201591-A1 | ISONICOTINAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2011-08-18 | — | — | US | disclosed |
| US-20110201591-A1 | ISONICOTINAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2011-08-18 | — | — | US | disclosed |
| EP-2350010-A1 | ISONICOTINAMIDE OREXIN RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010051236-A1 | ISONICOTINAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-05-06 | — | — | WO | disclosed |
| WO-2010051236-A1 | ISONICOTINAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066453-A1 | SERINE/THREONINE KINASE INHIBITORS | MAP3K1, MAP3K2, MAP3K20 | HSD17B10 2962/4885TSHR 2085/4885LCK 165/4885 |
| US-20110201591-A1 | ISONICOTINAMIDE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NTSR2 | HSD17B10 2672/4885TSHR 205/4885LCK 1987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.